| Sep 11 |
Sanofi reports positive Phase 3 results for Dupixent for CSU
|
| Sep 11 |
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
|
| Sep 11 |
Regeneron, Sanofi report mixed outcomes in late-stage trials for Dupixent
|
| Sep 11 |
Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
|
| Sep 11 |
Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
|
| Sep 11 |
Sanofi inaugurates vaccine plant in Neuville-sur-Saône, France
|
| Sep 11 |
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
|
| Sep 11 |
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
|
| Sep 11 |
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
|
| Sep 10 |
Health Care Roundup: Market Talk
|
